Ortho Pharmaceutical's Ortho Tri-Cyclen tablets(norgestimate/estradiol) has been approved by the US Food and Drug Administration for the treatment of acne in women seeking contraception. It is said to be the first time an oral contraceptive has been cleared by the US regulatory authorities for such therapy, and the first low-dose birth control pill to be cleared for a noncontraceptive indication since the Pill was introduced over 35 years ago.
According to Ortho, in clinical trials, Ortho Tri-Cyclen showed improvement of acne similar to that seen in studies looking at the efficacy of benzoyl peroxide and topical or systemic antibiotics. Two randomized, double-blind, placebo-controlled studies demonstrated that improvement of acne was reported during use of Ortho Tri-Cyclen in more than 80% of the studies' participants.
"This is great news for the millions of women with acne who take or want to take birth control pills," according to Geoffrey Redmond, president of the Foundation for Developmental Endocrinology. These studies, he added, "suggest that Ortho Tri-Cyclen treats acne at its source by decreasing the level of hormones that contribute to the development of acne."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze